Setting Priorities for HIV/AIDS Interventions
Show Less

Setting Priorities for HIV/AIDS Interventions

A Cost–Benefit Approach

Robert J. Brent

HIV/AIDS is much too complex a phenomenon to be understood only by reference to common sense and ethical codes. This book presents the cost–benefit analysis (CBA) framework in a well-researched and accessible manner to ensure that the most important considerations are recognized and incorporated.
Buy Book in Print
Show Summary Details
You do not have access to this content

Chapter 42: Conclusions I: How Not to Set Priorities for HIV

Robert J. Brent


It is time to sum up what CBA has to offer in the setting of priorities for interventions to deal with HIV/AIDS. In this chapter we look at three main ways that priorities are set in practice that do not rely on CBA methods. We see that all sorts of mistakes, and hence a large waste of resources, follow from ignoring CBA. Then in the next, and final, chapter we show how many concerns that people have, which are thought to be essential in setting priorities, are indeed included in CBA automatically. 1. EVALUATING BY LABELING In the HIV/AIDS field, many judgments are made about projects just by looking at the label associated with the intervention. Here we look at some of the main labels and explain why they are not helpful. (i) “Prevention” is Better than Cure A British saying is that “A penny’s worth of prevention is worth a pound’s worth of cure”. How can this not be true for HIV/AIDS interventions? There are two main surveys of a large number of HIV/AIDS evaluations by Creese et al. (2002) and Canning (2006). These surveys show clearly that treatment cost-effectiveness ratios are so much lower (we get so many more DALYs per dollar of expenditure) for prevention programs (such as condoms, blood safety, education and information) than for treatment projects (such as investing in ARVs). Surely, prevention is the way to go? Not necessarily. Here are some reservations: ● Even if every prevention program were more cost-effective than every treatment...

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information

or login to access all content.